NCT05714592Recruiting
Evaluation of Optical Genome Mapping in Phi Negative Myeloproliferative Neoplasia in the Detection of Acquired Cytogenetic Abnormalities
Source: ClinicalTrials.gov · Last updated 28 May 2026
Brief summary (registry, in English)
Standard cytogenetics (CBA +/- FISH) is of diagnostic and prognostic interest in Ph- MPN. However, its value is limited by the low frequency of detected abnormalities. The development of tools to increase the sensitivity of detection of chromosomal alterations is therefore particularly adapted to these pathologies. Optical genome mapping (OGM) is a high resolution "long read" technique that allows the identification of structural and copy number variations at the whole genome level. Several recent studies suggest that OGM is a future tool for cytogenetic characterization of haematological disorders. Its ability to describe structural abnormalities, including balanced ones, represents a major advantage over currently used technologies. Thus, OGM seems to be the key tool for cytogenetics of haematological malignancies in the coming years, making it possible to replace, under certain conditions, not only karyotype and FISH, but CMA and even RT-MLPA for the search for fusion transcripts, thus filling in the gaps in these techniques while maintaining their advantages. To define the place of this technology in Ph- MPN, the investigators will perform a OGM analysis on patients with Ph-MPN for whom bone marrow exploration is scheduled. These results will be compared with those of standard cytogenetics (CBA +/- FISH).
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- First submitted
- 27 Jan 2023
- Start date
- 17 May 2023
- Primary completion date
- 18 May 2027
- Lead sponsor
- Centre Hospitalier Universitaire, Amiens
- Diseases
- Myeloproliferative neoplasms
- NCT number
- NCT05714592
What you commit to
- Study type: Interventional
- Planned participants: 300
- From 17 May 2023 to the primary completion date, 18 May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patient with BCR::ABL positive myeloproliferative neoplasia.
- Person with a medical history that may impair the ability to understand the information notice
Who the study is looking for
- Patient 18 years of age or older
- Diagnosis or follow-up of polycythemia vera, essential thrombocythemia or primary or secondary myelofibrosis
- Requires bone marrow cytogenetics at diagnosis or follow-up
- Understanding of the French language
- Information of the patient and collection of no objection
- Person affiliated to a social security regime
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Hospitalier Universitaire d'Amiens Coordinator of this site? Confirm its status | Amiens | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.